Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL2 | P60568 | 7/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.41 |
| ▸ | STIM1 | Q13586 | 2/20 | 0.39 |
| ▸ | ORAI1 | Q96D31 | 2/20 | 0.39 |
| ▸ | TNF | P01375 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16637313 | 0.88 | TP53 (0.42) | IL2TP53MAPTHTTJAK2 | |
| SCHEMBL16637004 | 0.85 | IL2 (0.39) | IL2TP53MAPTHTTJAK2 | |
| SCHEMBL16636502 | 0.84 | JAK2 (0.40) | IL2TP53MAPTHTTJAK2 | |
| SCHEMBL16636792 | 0.83 | CRACR2A (0.42) | IL2TP53MAPTHTTJAK2 | |
| SCHEMBL16636498 | 0.81 | CRACR2A (0.47) | IL2TP53MAPTHTTJAK2 | |
| SCHEMBL16636744 | 0.81 | IL2 (0.48) | IL2TP53MAPTHTTJAK2 | |
| SCHEMBL16636848 | 0.80 | MGAM (0.37) | IL2TP53MAPTMEN1KMT2A | |
| SCHEMBL18038398 | 0.80 | BUB1 (0.39) | TP53MAPTHTTJAK2JAK1 | |
| SCHEMBL29420780 | 0.80 | BUB1 (0.39) | TP53MAPTHTTJAK2JAK1 | |
| SCHEMBL16636671 | 0.80 | MEN1 (0.37) | TP53MAPTMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9611263-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-9611263-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-9611263-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-20160229845-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2016-08-11 | — | — | US | disclosed |
| US-20160229845-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2016-08-11 | — | — | US | disclosed |
| US-20160229845-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2016-08-11 | — | — | US | disclosed |
| WO-2015054283-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2015-04-16 | — | — | WO | disclosed |
| WO-2015054283-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229845-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | IL2 3716/4885TP53 2681/4885MAPT 1478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.